YDYeli Ding

Yeli Ding

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yeli Ding has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Fei Wang

    Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi, China.

    1 shared publication
  • Rui Jia

    Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi, China.

    1 shared publication
  • Tiaohao Li

    Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi, China.

    1 shared publication
  • Xiaojuan Gao

    Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi, China.

    1 shared publication
  • Yanling Sun

    Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi, China.

    1 shared publication
  • Yujuan Wang

    Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi, China.

    1 shared publication

Latest Publications

  • Open Access

    Astragaloside IV inhibits idiopathic pulmonary fibrosis through activation of autophagy by miR-21-mediated PTEN/PI3K/AKT/mTOR pathway

    by Tiaohao Li, Xiaojuan Gao, Rui Jia, Yanling Sun, Yeli Ding, Fei Wang, Yujuan Wang

    As the main active ingredient of Astragalus, Astragaloside IV (AS-IV) can ameliorate pulmonary fibrosis. In this experiment, we studied how AS-IV reduces idiopathic pulmonary fibrosis (IPF). Bleomycin (BLM) or TGF‐β1 was treated in mice or alveolar epithelial cells to mimic IPF in vivo as well as in vitro. ASV-IV alleviated levels of inflammatory cytokines and fibrosis markers in IPF model. Through detection of autophagy-related genes, ASV-IV was observed to induce autophagy in IPF. Besides, ASV-IV inhibited miR-21 expression in IPF models, and overexpression of miR-21 could reverse the protective potential of ASV-IV on IPF. PTEN was targeted by miR-21 and was up-regulated by ASV-IV in IPF models. In addition, levels of inflammatory cytokines and fibrosis markers, autophagy, as well as the PI3K/AKT/mTOR pathway regulated by ASV-IV could be neutralized after treatment with autophagy inhibitors, miR-21 mimics, or si-PTEN. Our study demonstrates that ASV-IV inhibits IPF through activation of autophagy by miR-21-mediated PTEN/PI3K/AKT/mTOR pathway, suggesting that ASV-IV could be acted to be a promising therapeutic method for IPF.